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Objective: The objective of this article is to evaluate the safety and clinical outcome of ritux-
imab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care
therapy in a real-life setting in Germany. Methods: The GRAID registry included patients
with different autoimmune diseases who were given off-label treatment with rituximab. Data
on safety and clinical response were collected retrospectively. In SLE patients, clinical par-
ameters included tender and swollen joint counts, fatigue, myalgia, general wellbeing,
Raynaud’s and the SLEDAI index. Laboratory tests included dsDNA antibody titres, com-
plement factors, hematologic parameters and proteinuria. Finally, the investigators rated their
patients as non-, partial or complete responders based on clinical grounds. Results: Data from
85 SLE patients were collected, 69 female and 16 male, with a mean disease duration of 9.8
years. The mean follow-up period was 9.6 7.4 months, resulting in 66.8 patient years of
observation. A complete response was reported in 37 patients (46.8%), partial response in 27
(34.2%), no response in 15 (19.0%). On average, major clinical as well as laboratory efficacy
parameters improved substantially, with the SLEDAI decreasing significantly from 12.2 to 3.3
points. Concerning safety, one infusion reaction leading to discontinuation of treatment
occurred. Infections were reported with a rate of 19.5 (including six severe infections) per
100 patient years. Conclusion: With the restrictions of a retrospective data collection, the
results of this study confirm data of other registries, which suggest a favourable benefit-risk
ratio of rituximab in patients with treatment-refractory SLE. Lupus (2013) 22, 1142–1149.
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Introduction
The role of B cells in the pathogenesis of systemic
lupus erythematosus (SLE) and other systemic
autoimmune diseases is widely acknowledged.1 It
is not only their function as precursors to anti-
body-producing cells, but also their ability to pre-
sent antigen and to activate T cells as well as their
ability to secrete various pro-inﬂammatory cyto-
kines, which makes them a promising target in
autoimmune disorders such as SLE.2,3 The theoret-
ical concept is supported by a large body of reports
that describe a successful intervention in a number
of autoimmune diseases by either B cell depletion
or modulation.4
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Rituximab is a B cell-depleting anti-CD20 anti-
body which has recently been approved as ﬁrst-line
therapy for antineutrophil cytoplasmic antibody
(ANCA)-associated small vessel vasculitides
(AAV) by the United States Food and Drug
Administration (FDA) and the European Medical
Agency (EMA), making AAV the third indication
for rituximab besides lymphoma and rheumatoid
arthritis (RA).5,6 In addition, rituximab has been
used for oﬀ-label treatment of refractory SLE for
more than 10 years.7–9 However, two recent rando-
mized controlled trials with rituximab in SLE
(EXPLORER) and lupus nephritis (LUNAR) did
not reach their primary eﬃcacy endpoints.10,11
There has been much debate about the reasons for
this lackof evidence and concerns about the designof
these trials as clinical experience of many experts in
the ﬁeld and results of large open-label studies favour
the use of rituximab in this disease.12–16
Although further clinical trials may be launched
to further investigate the eﬃcacy of rituximab in
SLE, it is unlikely that approval of rituximab for
SLE will be gained in the near future. Given the
urgent need for eﬀective, safe and tolerable treat-
ment options for SLE patients, in particular in dis-
ease refractory to standard measures of care, it is of
great importance that experiences with the oﬀ-label
use of rituximab are collected and made accessible
to physicians treating these patients.17
The German Registry of Autoimmune Diseases
(GRAID) has been established to provide further
evidence on the safety and clinical outcomes of
rituximab in patients with diﬀerent autoimmune
diseases on a retrospective basis. It includes not
exclusively rheumatologic, but also dermatologic,
neurologic and nephrologic cases which have been
refractory to standard of care treatment and there-
fore have been treated with oﬀ-label rituximab. An
overview of the observations in the registry has
been published recently.18 This manuscript focuses
on the data of the SLE patients, which represented
the largest population within GRAID.
Patients and methods
The design of this trial was a multicentre, non-
interventional retrospective data collection of
adult patients with diﬀerent autoimmune disorders,
who had received rituximab on an oﬀ-label basis as
deemed necessary by their treating physicians.
General reasons for rituximab treatment in this
cohort were inadequate response to, side eﬀects
of and/or contraindications for the preceding
SLE treatments. Ineﬃcacy was deﬁned as recurrent
and/or persistent SLE symptoms according to the
treating physician despite combination therapy
with glucocorticoids and disease-modifying anti-
rheumatic drugs (DMARDs) or cyclophospha-
mide. Patients with diagnoses approved for
treatment with rituximab, e.g. RA or non-
Hodgkin’s lymphoma, were not included.
Rituximab was either added to or replaced the con-
current immunosuppressive therapy. The diagnosis
of SLE and its clinical manifestations such as sero-
sitis and anaemia, etc., were based on the judge-
ment of the treating physicians, who were
requested to include only patients fulﬁlling the cur-
rent American College of Rheumatology (ACR)
criteria for SLE.19 Lupus nephritis was included if
results of renal biopsies were consistent with the
diagnosis. Safety of Estrogens in Lupus
Erythematosus National Assessment-Systemic
Lupus Erythematosus Disease Activity Index
(SELENA-SLEDAI) scores at baseline and at last
follow-up were calculated as speciﬁed previously if
appropriate data were available.20 All laboratory
tests such as assessment of complement levels and
anti-double-stranded DNA (anti-dsDNA) antibo-
dies were performed at the sites.
Because of the diversity of included diagnoses
and the retrospective nature of the survey, eﬃcacy
assessments were restricted to a categorization of
complete response, partial response and no
response, as judged at the discretion of the treating
physician. Additionally, the investigators estimated
the patients’ wellbeing on a 100mm visual analogue
scale (VAS). Response of rituximab in SLE patients
was further evaluated by comparison of mean
SELENA-SLEDAI scores at baseline and after
last infusion. Other instruments of eﬃcacy assess-
ment included the percentage of patients with nor-
malization of complement and dsDNA antibody
levels and the proportion of patients with cortico-
steroid reduction.
Safety assessments included the registration of
adverse events (AE) and serious AEs during the
treatment and follow-up period as well as all
adverse reactions that occurred during or within
24 hours of rituximab infusions. The intensity of
AEs was graded using the National Cancer
Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE), version 3 or a
grade 1–5 severity scale.21 Infections were classiﬁed
as serious if they led to intravenous (i.v.) antibiotic
treatment, hospitalization or death. The speciﬁca-
tion of the severity of infections as mild, moderate
and severe was based on the treating investigators’
estimation.
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Data entry for GRAID occurred via Web-based
electronic case report forms between December
2008 and July 2009. Participating physicians came
from 42 hospital and private practice centres in
Germany and were not only rheumatologists, but
also haematologists, nephrologists, neurologists,
dermatologists and other internal medicine special-
ists as well.
Ethical approval and approval by the local data
protection agency were obtained by Charite´
Universitaetsmedizin Berlin. Local approval was
obtained by the principal investigators if required
by local regulations. Statistical analysis was per-
formed with Prism 5 software for Mac OS X
using two-tailed t- and Chi-square tests. P values
of less than 0.05 were considered signiﬁcant.
Results
Baseline and treatment characteristics
Among the 370 patients reported to the GRAID
registry, 85 (23.0%) had a diagnosis of SLE, repre-
senting the most common GRAID disorder. Sixty-
nine (81.0%) SLE patients were female. The mean
disease duration was 9.8 8 years. Before rituxi-
mab treatment, the most common SLE manifest-
ations in the cohort were fatigue (48.2%),
erythema (42.4%), anaemia (38.8%), myalgia
(34.1%) and arthritis (29.4%). In addition, 36.5%
of the patients had biopsy-proven lupus nephritis.
Reasons for the use of rituximab in this cohort
were ineﬃcacy, side eﬀects and/or contraindica-
tions to preceding treatments in 71 (89.9%), 25
(31.6%) and 11 (13.9%) patients, respectively.
Independent side eﬀects included nausea, bone
marrow toxicity and renal insuﬃciency, among
others. Advanced renal insuﬃciency with a glom-
erular ﬁltration rate (GFR) below 30ml/min is an
example of a contraindication to non-rituximab
treatments. In the group of patients with inad-
equate response to the preceding treatments, the
indications for rituximab were renal involvement,
i.e. glomerulonephritis and/or proteinuria, in 27
patients, haematologic manifestations, i.e. anaemia,
leucopenia and/or thrombocytopenia, in 21
patients, central nervous system involvement in
seven patients, skin involvement in six patients,
serositis in three patients and other reasons, e.g.
arthritis, in 15 patients. In two patients, non-com-
pliance with conventional treatment was the reason
for the use of rituximab.
Prior to the ﬁrst course of rituximab, all patients
had been treated with corticosteroids, 41.8% with
mycophenolate mofetil, 39.2% with azathioprine,
34.2% with antimalarials, 32.9% with cyclophos-
phamide, 20.2% with methotrexate, 11.4% with
i.v. immunoglobulins (IvIgs) and 8.9% with leﬂu-
nomide. During rituximab therapy, concomitant
treatment consisted of corticosteroids in 92.4%,
mycophenolate mofetil in 30.4%, antimalarials in
29.1%, azathioprine in 11.4%, cyclophosphamide
in 7.6%, methotrexate in 3.8%, IvIg in 3.8%
and others in 2.5%. An overview of the baseline
characteristics of the SLE population is shown in
Table 1.
Sixty-seven (78.8%), 16 (18.8%) and two (2.4%)
of the patients received one, two and three treat-
ment courses, respectively. A treatment course was
deﬁned as two infusions of rituximab in a two-week
interval. The mean interval between two treatment
Table 1 Overview of the baseline characteristics of the
GRAID SLE cohort
Epidemiology
Patients treated, n 85
Female (%) 81.0%
age at first infusiona (years) 36.6
disease durationa (years with SD) 9.8 8.0
Key clinical features
Fatigue (%) 48.2
Erythema (%) 42.4
Myalgia (%) 34.1
Arthritis (%) 29.4
Lupus nephritis (%) 36.7
SELENA-SLEDAI scorea 12.2 7.4
Biomarkers
ESRa (mm/h) 36.0 25.3
C3a (mg/dl) 68.3 36.6
C4a (mg/dl) 10.8 9.1
Elevated ANA titre (%) 84.1
Elevated dsDNA antibodies (%) 73.4
Proteinuria (%) 38.8
Concomitant medications (%)
Corticosteroids 92.4
Mycophenolate mofetil 30.4
Antimalarials 29.1
Azathioprine 11.4
Cyclophosphamide 7.6
Methotrexate 3.8
IvIg 3.8
Other 2.5
GRAID: German Registry of Autoimmune Diseases; SLE: systemic
lupus erythematosus; SELENA-SLEDAI: Safety of Estrogens in
Lupus Erythematosus National Assessment-Systemic Lupus
Erythematosus Disease Activity Index; ESR: erythrocyte sedimenta-
tion rate; ANA: antinuclear antibodies; dsDNA: double-stranded
DNA; IvIg: intravenous immunoglobulin. aMeans with standard devi-
ation (SD); reference values: ESR:< 20mm/h (male),< 30mm/h
(female), C3: 90–180mg/dl, C4: 10–40mg/dl, dsDNA antibodies posi-
tive according to cut-off values of local laboratories, protein-
uria> 150mg/24 hours.
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courses was 13 9 months (median 10 months).
The mean dosage of rituximab per treatment
course was 1887 670mg (median 2000mg). The
mean follow-up period, deﬁned as the time between
the ﬁrst infusion and 180 days after the last infu-
sion, was 9.6 7.4 months, summing up to 66.8
patient years of observation. Rituximab treatment
was ongoing at the time of data collection in 66 of
the 85 patients, while 19 had discontinued rituxi-
mab infusions. The reasons were inadequate
response in 14, adverse reactions in three, and
both reasons in one patient. For another patient
the reason for treatment discontinuation was not
documented. Details of the rituximab treatment
are given in Table 2.
Efficacy assessment
The global treatment response as estimated by the
treating physicians was complete in 37 (46.8%),
partial in 27 (34.2%) and none in 15 (19.0%) of
the SLE patients (Figure 1). In addition, the value
for general wellbeing as marked on a 100mm VAS
increased signiﬁcantly from a mean of 49.2 before
the initiation of rituximab treatment to 64.3 at the
last visit (p< 0.05). Mean SELENA-SLEDAI
scores decreased signiﬁcantly from 12.2 to 3.3
during rituximab treatment (p< 0.05). Major dis-
ease manifestations such as general, dermatologic
and haematologic involvements signiﬁcantly
improved upon rituximab treatment. Speciﬁcally,
the presence of the following signs and symptoms
decreased signiﬁcantly: the general manifestations
fever (20.0% to 8.2%), weight loss (11.8% to
2.4%), fatigue (48.2% to 28.2%), the presence of
the skin symptoms erythema (42.4% to 21.2%),
mucocutaneous involvement (21.2% to 10.6%)
and Raynaud’s syndrome (35.3% to 18.8%), pleur-
itic symptoms (12.9% to 3.5%), the haematologic
manifestations anaemia (38.8% to 23.5%), leuco-
penia (20.5% to 9.1%) and thrombocytopenia
(32.9% to 11.8%), and ﬁnally glomerulonephritis
(36.5% to 21.5%), with p< 0.05 each. Other mani-
festations such as musculoskeletal and neurologic
manifestations also improved but did not reach
statistical signiﬁcance (Figure 2). Although the pro-
portion of patients requiring prednisone did not
diﬀer signiﬁcantly before and after rituximab
(86.1% vs 84.8%), the necessity for i.v. methylpred-
nisone use could be reduced signiﬁcantly (12.7% vs
1.3%, p< 0.05).
Concerning laboratory markers of activity,
68.1% and 62.7% of the patients had low C3 and
C4 complement levels at baseline, respectively,
compared to 33.3% and 43.8% at last visit
(p< 0.05 each). Mean complement C3 and C4
levels increased from 68.3 to 77.5mg/dl and from
10.8 to 12.4mg/dl, respectively (not signiﬁcant).
Further, the proportion of patients with leucopenia
was reduced signiﬁcantly from 20.5% to 9.1%
(p< 0.05). Although not statistically signiﬁcant,
the proportion of patients with elevated dsDNA
antibody levels decreased from 73.4% to 62.2%.
The proportion of patients with proteinuria, sig-
niﬁcant proteinuria and elevated erythrocyte sedi-
mentation rate did not change signiﬁcantly when
pre- and post-rituximab values were compared
(Table 3).
Safety assessment
Adverse reactions occurring during infusions or
within 24 hours were reported in 18 of the 85
(21.2%) SLE patients. Five of these were deﬁned
as allergic reactions (5.9%). Only one of the infu-
sion-related reactions resulted in a permanent treat-
ment discontinuation. The overall rate of infections
was 19.5 per 100 patient years, including a rate of
Table 2 Details of rituximab treatments in the GRAID SLE
cohort
Courses of rituximab n (%)
1 67 (78.8)
2 16 (18.8)
3 2 (2.4)
Dosage per course (mean mg with SD) 1887 670
Total dosage per patient (mean mg with SD) 2331 1033
Time between two courses (mean months with SD) 13 9
Rituximab discontinued (%) 19 (22.4)
Inadequate response 14
Side effects 3
Others 2
GRAID: German Registry of Autoimmune Diseases; SLE: systemic
lupus erythematosus; SD: standard deviation.
no response
partial response
complete response
46.8%
34.2%
19.0%
Figure 1 Assessment of treatment response to rituximab
according to the physicians’ judgement (see Results for details).
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severe infections of six per 100 patient years.
Twelve of 85 patients experienced a total of 12
infections, of which four were reported as mild,
four as moderate and four as severe. Nine infec-
tions were identiﬁed to be of bacterial, two of
viral and one of fungal origin. Among the bacterial
infections were reports of Listeria meningitis, cellu-
litis, pseudomembranous colitis and Salmonella
infection. One of the viral infections was classiﬁed
as herpes labialis, the fungal infection was a can-
dida esophagitis. Eight of the 12 reported infections
led to hospitalization and four of these required i.v.
antibiotic treatment (Tables 4 and 5). One patient
with a diagnosed antiphospholipid syndrome
experienced a deep vein thrombosis. No other rele-
vant AEs and no deaths occurred during the treat-
ment period and within six months after the last
infusion.
0 20 40 60
lymphadenopathy
leucopenia
anaemia
other neuro
seizures
pns
cns
other kidney
proteinuria
pulmonary hypertension
fibrosis
ascites
myalgia
arthralgia
mucosal lesions
raynaud
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fever 1st infusion
last control
*
*
*
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*
*
*
*
*thrombocytopenia
Figure 2 Comparison of the prevalences of lupus manifestations at first infusion of rituximab and at last follow-up.
(*: p< 0.05). CNS: central nervous system; PNS: peripheral nervous system; musc.-skel.: muskuloskeletal.
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Discussion
The subgroup of SLE patients represents the largest
within the GRAID registry, which was initiated to
document safety and eﬃcacy of rituximab oﬀ-label
use in diﬀerent autoimmune diseases. Data on
rituximab use in the SLE population have become
even more important, since two randomized con-
trolled trials failed to prove the eﬃcacy of the drug
in SLE and lupus nephritis.10,11 Concerns regarding
the design of these trials became apparent immedi-
ately after their publication, as a substantial
number of reports and personal experience of
many experts in the ﬁeld has seen a quite convin-
cing eﬀect of the drug in SLE.12,13 Further evidence
for the usefulness of B-cell targeting therapies
comes from the recently approved belimumab,
which blocks the B-lymphocyte stimulator BLyS
and which has shown eﬃcacy in treating refractory
SLE.22–24
Despite the retrospective nature of GRAID, we
present data from a representative SLE cohort. As
can be expected in the oﬀ-label setting of rituximab
treatment in SLE, the cohort features comparably
active and severe disease as indicated by a baseline
mean SELENA-SLEDAI of 12.2 and 36.7% of
patients with biopsy-proven lupus nephritis.
Nonetheless, a structured eﬃcacy assessment as
usually adopted in a prospective clinical trial was
not possible. In addition, the heterogeneity of the
disease further complicates the assessment of dis-
ease activity. Further, assessment tools like the
SELENA-SLEDAI or the British Isles Lupus
Activity Group (BILAG) score, which have been
developed to cover the multiple disease manifest-
ations, are time consuming and less feasible for
daily clinical practice.25 For these reasons, the
Table 5 Overview of characteristics and outcome of reported infections
No. Diagnosis Grade Hospitalization I.v. antibiotic Outcome
1 Pseudomembranous colitis Severe Yes No Resolved
2 Bacterial meningitis Severe Yes Yes Resolved
3 Cellulitis of the hand Severe Yes Yes Resolved
4 Meningitis (L. monocytogenes) Severe Yes Yes Resolved
5 Viral infectiona Moderate Yes Yes Resolved
6 Tracheobronchitis Moderate Yes No Resolved
7 Not specified Moderate Not specified Not specified Resolved
8 Soor esophagitis Moderate Yes No Resolved
9 Bacterial infectiona Mild No No Resolved
10 Herpes labialis Mild No No Resolved
11 Urinary tract infection (E. coli) Mild No No Resolved
12 Bacterial infectiona Mild No No Resolved
I.v.: intravenous. aNot further specified.
Table 3 Effect of rituximab treatment on selected clinical and
laboratory parameters of SLE activity; means with standard
deviation for SELENA-SLEDAI
First infusion Last control p
SELENA-SLEDAI 12.2 7.4 3.3 3.1 < 0.05
Leucopenia (%) 20.5 9.1 < 0.05
Elevated ESR (%) 64.6 60.9 0.72
Low C3 (%) 68.1 33.3 < 0.05
Low C4 (%) 62.7 43.8 < 0.05
Elevated dsDNA antibodies (%) 73.4 62.2 0.29
Any proteinuria (%) 38.8 39.2 0.98
Proteinuria> 500mg/24 hours (%) 27.1 16.5 0.13
SLE: systemic lupus erythematosus; SELENA-SLEDAI: Safety of
Estrogens in Lupus Erythematosus National Assessment-Systemic
Lupus Erythematosus Disease Activity Index; ESR: erythrocyte sedi-
mentation rate; dsDNA: double-stranded DNA. Reference values:
leucocytes: 4.0–11.0 103/ml, ESR:< 20mm/h (male),< 30mm/h
(female), C3: 90–180mg/dl, C4: 10–40mg/dl, dsDNA antibodies posi-
tive according to cut-off values of local laboratories, protein-
uria> 150mg/24 hours.
Table 4 Overview of adverse and serious adverse events
n (%)
Infusion relateda
Infusion reactions 6 (7.1)
Allergic reactions 5 (5.9)
Other reaction 7 (8.2)
Reaction leading to permanent discontinuation 1 (1.2)
Clinically relevant infectionsb
None 73 (85.9)
Mild 4 (4.7)
Moderate 4 (4.7)
Severe 4 (4.7)
Observation period (patient years) 66.8
Infections per 100 patient years 19.5
Severe infections per 100 patient years 6.0
Deaths 0
aDuring or up to 24 hours after infusion; bUp to six months after
infusion.
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general clinical impression of the treating phys-
ician, taking into account the patient history and
the laboratory values, is likely to be a good alter-
native to assess the treatment response in the set-
ting of our study.
Taking this as a key parameter, rituximab treat-
ment showed excellent eﬃcacy in the GRAID SLE
population (Figure 1). A possible bias may have
been introduced by the non-blinded fashion of the
study and the fact that the physician prescribing an
oﬀ-label medication is convinced of its usefulness.
However, in the light of the impressive treatment
responses across many disease features, it is unli-
kely that this bias spoils the overall conclusions. In
regard to the eﬀect of speciﬁc disease features, gen-
eral disease manifestations as well as dermatologic
and haematologic manifestations showed best, i.e.
signiﬁcant improvements with treatment of rituxi-
mab, while manifestations such as musculoskeletal
disease manifestations showed a trend towards
improvement that did not reach statistical signiﬁ-
cance (Figure 2). In addition, SELENA-SLEDAI
scores as well as laboratory markers of disease
activity such as the proportion of patients with
leucopenia or abnormal complement levels
improved signiﬁcantly while others showed a ten-
dency for improvement, e.g. the proportion of
dsDNA antibody positivity (Table 3). These eﬀects
on SLE manifestations are consistent with previ-
ously published reports on the use of rituximab in
SLE.8,26,27
A strength of data from a real-life setting in con-
trast to a clinical trial is that patients can be
included who otherwise would not qualify for a
clinical trial because of concomitant diseases or
treatments. This is of particular importance for
the safety assessment of a drug. In this regard,
our data on safety show comparable results to
those published for RA and SLE clinical trials
and post-approval registries.28,29 Infusion-related
reactions have been reported quite frequently
but have rarely led to treatment discontinuation
(Table 4). The slightly higher rates of overall and
of severe infections may generate from the higher
disease burden of SLE and the frequent use of more
aggressive immunosuppressants than in an RA
population.30,31 For example, all patients in the
cohort had a pretreatment with corticosteroids
and one-third of them with cyclophosphamide.
Therefore, a rate of six severe infections per 100
patient years does not seem unexpected (Table 5).
The kind of infections is also similar to the experi-
ence in RA patients.32,33
This cohort adds to registry data from other
countries, which have all shown a substantial
eﬀect of rituximab in the treatment of SLE.12,34,35
The French Autoimmunity and Rituximab (AIR)
registry, for example, investigated the eﬃcacy of
rituximab in 136 SLE patients, of whom 40 patients
had biopsy-proven lupus nephritis. In regard to the
general baseline characteristics and the assessment
of eﬃcacy, both cohorts are comparable. The over-
all response rates as estimated by the treating phys-
icians were similar with 83% in the French and
81% in our cohort. Although not directly compar-
able, SELENA-SLEDAI responses as well as mani-
festation-speciﬁc responses were also similar.
Concerning safety issues, two severe infusion reac-
tions and ﬁve serum-sickness-like reactions
occurred in AIR. Twelve (9%) patients had severe
infections, of whom ﬁve died because of infection.
Because of AEs, rituximab had to be discontinued
in 12 patients in AIR. In addition, the Spanish
LESIMAB registry evaluated rituximab treatment
in 116 SLE patients. Complete response was
deﬁned as a SELENA-SLEDAI score of  2 with
a SELENA-SLEDAI ﬂare index of 0; partial
response was deﬁned as a reduction in the
SELENA-SLEDAI score of  4 with no new or
worsening of symptoms. According to that,
62.9% achieved an overall response by month 6.
The median time to response was 6.5 months. A
total of 38.1% of the patients relapsed after the
ﬁrst infusion. Of note, their rate of serious infec-
tions was 12.6 per 100 patient years compared to
6.0 per 100 patient years in the GRAID registry.
Together with these data from other European
registries, our results show that the oﬀ-label use of
rituximab in treatment-refractory SLE is common,
eﬃcacious and seems to have an acceptable risk
proﬁle.
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